RT Journal Article
SR Electronic
T1 SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20131789
DO 10.1101/2020.07.15.20131789
A1 Fajnzylber, Jesse
A1 Regan, James
A1 Coxen, Kendyll
A1 Corry, Heather
A1 Wong, Colline
A1 Rosenthal, Alexandra
A1 Worrall, Daniel
A1 Giguel, Francoise
A1 Piechocka-Trocha, Alicja
A1 Atyeo, Caroline
A1 Fischinger, Stephanie
A1 Chan, Andrew
A1 Flaherty, Keith T.
A1 Hall, Kathryn
A1 Dougan, Michael
A1 Ryan, Edward T.
A1 Gillespie, Elizabeth
A1 Chishti, Rida
A1 Li, Yijia
A1 Jilg, Nikolaus
A1 Hanidziar, Dusan
A1 Baron, Rebecca M.
A1 Baden, Lindsey
A1 Tsibris, Athe M.
A1 Armstrong, Katrina A.
A1 Kuritzkes, Daniel R.
A1 Alter, Galit
A1 Walker, Bruce D.
A1 Yu, Xu
A1 Li, Jonathan Z.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.15.20131789.abstract
AB The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). We quantified SARS-CoV-2 viral load from participants with a diverse range of COVID-19 severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. SARS-CoV-2 plasma RNA was detected in 27% of hospitalized participants and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, higher prevalence of detectable SARS-CoV-2 plasma viral load was associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, were associated with increased risk of mortality. SARS-CoV-2 viral load may aid in the risk stratification of patients with COVID-19 and its role in disease pathogenesis should be further explored.Competing Interest StatementDr. Li has consulted for Abbvie and Jan Biotech. Dr. Alter is the founder of Seromyx Inc.Funding StatementThis study was supported in part by the Massachusetts Consortium for Pathogen Readiness through grants from the Evergrande Fund, Mark and Lisa Schwartz (to Drs. Li and Yu), Nancy Zimmerman (to Dr. Alter), NIH grants U01AI106701 (to Dr. Li), by the Harvard University Center for AIDS Research (NIAID 5P30AI060354), 3R37AI080289 (to Dr. Alter), CDC grant U01CK000490 (to Dr. Ryan), and the SAMANA Kay MGH Scholar program (to Dr. Alter).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Partners Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests can be made to the corresponding author.